CD19/CD22 CAR T Cell Treatment for High-Risk Pediatric Acute Lymphoblastic Leukemia

Mon, 13 Apr 2026 02:31:19 +0000
Intellectual Property

The USPTO published patent application US20260097122A1 for CD19/CD22 chimeric antigen receptor (CAR) T-cell products and methods for treating high-risk or relapsed CD19+ or CD22+ haematological malignancies, specifically pediatric acute lymphoblastic leukemia. The application was filed on May 10, 2023, under application number 18862269. Inventors include Martin Pulé, Persis Amrolia, and Sara Ghorashian.